Impact of the Glycemic Control and Duration of Type 2 Diabetes on Vitamin D Level and Cardiovascular Disease Risk

Table 6

Cardiovascular disease risk among study groups vs. normal control.

Groups	Full CVD patient risk	Hard CVD patient risk	ASCVD risk 10 year	Lifetime ASCVD risk
Normal
NC
NU
LC
LU
(between group)	29.837	21.33	2.418	23.888
(value)	<0.0001	<0.0001	0.056	<0.0001
Post hoc test
N vs. NC	<0.0001	<0.0001	0.323	<0.0001
N vs. NU	<0.0001	<0.0001	0.051	<0.0001
N vs. LC	<0.0001	<0.0001	0.149	<0.0001
N vs. LU	<0.0001	<0.0001	0.384	<0.0001
NC vs. NU	1.000	1.000	0.431	0.991
LC vs. LU	0.995	0.999	0.785	0.998
NC vs. LC	0.731	0.950	0.921	0.812
NU vs. LU	0.939	0.871	0.278	0.783

Note: data are presented as the . value for differences between groups according to ANOVA, significant if . Full cardiovascular disease: hard CVD or coronary insufficiency, angina pectoris, transient ischemic attack, intermittent claudication, or congestive heart failure. Hard cardiovascular disease: coronary death, myocardial infarction, or fatal or nonfatal stroke. ASCVD: atherosclerotic cardiovascular diseases defined as coronary heart disease death, nonfatal myocardial infraction, or fatal or nonfatal stroke.